BioSpace News Archive

MiMedx Group, Inc., a pioneer and leader in placental biologics, announced operating and financial results for the first quarter 2023, which ended March 31, 2023, including net sales of $71.7 million, net loss of $5.0 million and Adjusted EBITDA of $5.5 million.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the successful completion of the first cohort in the Phase 1b portion of its Phase 1b/2 clinical trial using Annamycin in combination with Cytarabine for the treatment of AML (MB-106).

In another first, Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, announces Voice Controls, a new feature powered by artificial intelligence (AI) that enables clinicians to control multiple imaging functions with voice commands, leaving their hands free to perform procedures and exams.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 randomized placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes certain dendritic cells, to treat people with active proliferative lupus nephritis (LN).

JOGO Health, a value-based virtual care company that leverages proprietary digital interventions to provide comprehensive rehabilitation for chronic pain and neuromuscular conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its chronic lower back pain product, JOGO-CLBP.

The Insight Partners published latest research report on “Biosafety Cabinet Market Size Report, Share, Growth, Trends & Forecasts to 2028 - COVID-19 Impact and Global Analysis By Products Handled, Category, Type, Application and End User”,

Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented at the Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida April 14-19, 2023.

RaySearch Laboraties AB announces that Yonsei Cancer Center in South Korea has treated its first patient using RayStation®* and RayCare®* for carbon ion radiation therapy.

Aurinia Pharmaceuticals Inc. announced that the Swiss Agency for Therapeutic Products has granted marketing authorization of LUPKYNIS® in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V lupus nephritis, a serious complication of systemic lupus erythematosus.

Photocure ASA, the Bladder Cancer Company, announces that results from the Nordic Registry demonstrating benefits of Blue Light Cystoscopy were presented at the AUA 2023 Conference: the American Urological Association Annual Congress 2023 which was held April 28 - May 1, 2023 in Chicago, IL, USA.